Recruiting Trials

Arrowhead Pharmaceuticals has a Phase 3, double-blind, placebo-controlled study evaluating the efficacy and safety of plozasiran in patients with severe hypertriglyceridemia (SHTG) at high risk for acute pancreatitis (SHASTA-5). Plozasiran is a synthetic, double-stranded, hepatocyte-targeted ribonucleic acid interference (RNAi) trigger designed to specifically silence mRNA transcripts from the APOC3 gene using an RNAi mechanism administered subcutaneously every three months. Enrollment into SHASTA-5 will be open to adults with an established diagnosis of SHTG (≥880 mg/dL or ≥10.0 mmol/L) and have experienced at least 2 episodes of hypertriglyceridemia induced acute pancreatitis. These participants are also willing to remain on a stable diet and stable background lipid-lowering therapy during the double-blind, placebo-controlled, randomized (1:1) treatment period, and open label extension study.

If you are a clinician and would like more information about SHASTA-5, please contact Arrowhead Pharmaceuticals at shasta@arrowheadpharma.com.

Arrowhead Pharmaceuticals has a Phase 3, double-blind, placebo-controlled study to evaluate the efficacy and safety of zodasiran in adolescent and adult patients with homozygous familial hypercholesterolemia (HoFH) (YOSEMITE). Zodasiran is a synthetic, double-stranded, hepatocyte-targeted ribonucleic acid interference (RNAi) trigger designed to specifically silence expression of ANGPTL3 mRNA. Study treatment (zodasiran or placebo) is administered subcutaneously at five timepoints over a 12 month period. Enrollment into YOSEMITE will be open to participants 12 years and older with an established diagnosis of HoFH, who are willing to remain on a stable diet and stable background lipid-lowering therapy during the 12-month, double-blind, placebo-controlled, randomized (2:1) treatment period.

If you are a clinician and would like more information about YOSEMITE, please contact Arrowhead Pharmaceuticals at YOSEMITE@arrowheadpharma.com.